Leveraging strong R&D platforms, Innovent has built a robust pipeline of 25 clinical-stage assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 5 products, including Tyvyt (sintilimab injection, PD-1 antibody), Byvasda (bevacizumab injection), Sulinno (adalimumab injection) and Halpryza (rituximab injection) approved by the National Medicine Products Administration (NMPA) for marketing in Mainland China and IBI375 (Pemigatinib, FGFR1/2/3 inhibitor) approved by Taiwan Food and Drug Administration (TFDA), 6 assets in pivotal clinical trials, and additional 14 molecules in early clinical stage.

Global E-waste Per Capita Generated by Year 2014-2030

Global E-waste Generated by Year 2014-2030

Global E-waste Generated by Item

Global E-waste Generated by Region in year 2014

Global E-waste Recycled by Region in year 2014

Covered Population

Percentage of Population Covered in E-Waste Management for year 2014, 2017, 2019

EEE Placed on the Market (in kt) in Uganda

E-waste generated (in kt) in Uganda

E-waste generated from households in Jordan in 2018 (in tons)

EEE Placed on the Market (in kt) in Bosnia and Herzegovina

E-waste generated (in kg per capita) in Bosnia and Herzegovin

EEE Placed on the Market (in kt) in Tanzania

E-waste status in Africa in 2019

E-waste status in the Americas in 2019

E-waste status in Asia in 2019

E-waste status in Europe in 2019

E-waste status in Oceania in 2019

Country wise Key Statistics for E-Waste